Influenza neuraminidase-specific B-cell receptor (NA-specific BCR) (NA-specific BCR)

The B-cell receptor (BCR) specific for influenza neuraminidase epitopes is a membrane-bound immunoglobulin complex on B lymphocytes that mediates the recognition of the influenza virus neuraminidase (NA) protein (Stadlbauer et al., 2019, Science). NA is a critical viral enzyme that facilitates the release of new viral particles from infected cells by cleaving sialic acid receptors (Memoli et al., 2016, J Infect Dis). When the BCR binds to specific epitopes on the NA protein, it triggers a signaling cascade that results in B-cell maturation and the production of NA-specific antibodies (Ellebedy et al., 2014, PNAS). These antibodies provide protection by inhibiting the enzymatic activity of NA, which complements the neutralizing effect of hemagglutinin-specific antibodies (Wan et al., 2020, Nature Communications). This BCR is a key target in the development of next-generation influenza vaccines, particularly those aiming for "universal" protection by targeting conserved epitopes across different viral strains (Wrammert et al., 2008, Nature). Understanding the repertoire and specificity of these BCRs is essential for designing immunogens that can elicit broad and potent immunity against seasonal and pandemic influenza.

Other names

B-cell receptor specific for influenza neuraminidase epitopesNeuraminidase-specific B-cell receptorNA-reactive BCRAnti-neuraminidase BCRInfluenza NA-specific BCR

Vaccine-delivered neuraminidase antigens bind to the NA-specific BCR, triggering intracellular signaling cascades (via Ig-alpha/Ig-beta) that lead to B-cell proliferation, affinity maturation, and differentiation into plasma cells that secrete neuraminidase-inhibiting (NAI) antibodies.